Development / Products in the Pipeline
      Medical Network
      Pharmaceutical Industry




















  • Documentation and Announcements

    Please click here to obtain MiLOC Group Limited Interims Announcement and Extension of Convertible Bond on 30 Sept 2021 in PDF format.

    Please click here to obtain the Announcement of the Notice of AGM on 10 Sept 2021 in PDF format.

  • Contact us

    MiLOC Group Limited
    Address : 8/F, Sino Cheer Plaza,

                      23 Jordan Road, Kowloon


    Rorrico is a TCM product for the treatment of influenza viruses, including the Influenza A virus and its sub-type virus, pandemic H1N1 or Swine flu. Rorrico’s formula contains 21 herbs. It is confected with, among other things, honeysuckle, radix isatidis, rhubarb, codonopsis pilosula, amomum villosum, malt and white atractylodes medicine and has the feature of heat-clearing and detoxification, blood stasis detoxification and righting detoxification.

    Clinical Trials
    Initial tests on Rorrico indicate that it has antiviral efficacy on the Influenza A (H1N1) virus, as evidenced by in-vitro research conducted by the Wuhan Institute of Medical Virology in the PRC between May and August 2009. The research states that Rorrico had the same effect as Tamiflu on anti-virus replication and biosynthesis. Tamiflu is the most frequently prescribed medicine for treating influenza.
    MIAR of the Macau University of Science and Technology was commissioned to conduct further clinical trials on human subjects to investigate the therapeutic and preventative effects of Rorrico on influenza viruses, in particular Influenza A viruses (including sub-type H1N1).

    Rorrico has passed safety testing conducted by the Chinese Medicines and Food Safety Laboratory of MIAR, which is ISO/IEC 17025 accredited by the National Association of Testing Authorities (Australia) (“NATA”). NATA was created in 1947 and is a founding member of the International Laboratory Accreditation Cooperation (ILAC) and the Asia Pacific Laboratory Accreditation Cooperation (APLAC), and provides both of their secretariats. The safety testing was conducted in accordance with the safety compliance requirements for TCM distribution registration established by the Department of Health, Macau. Rorrico will also need to pass safety testing in Hong Kong and China as part of completing the registration process in both of these jurisdictions. However, following the successful completion of safety testing in Macau, the Directors are confident that Rorrico will satisfy safety requirements in Hong Kong and China.

    , Hong Kong
    E-mail : info@miloc.com

    Tel  : 2110 4221
    Fax : 2110 4261